A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.

被引：0
|
作者：
Nauseef, Jones T.
Sun, Michael Philip
Thomas, Charlene
Bissassar, Mahelia
Patel, Amie
Tan, Angela
Fernandez, Escarleth
Davidson, Zachary
Chamberlain, Tessa
Earle, Kara
Wunder, Rebecca
Castellanos, Sandra Huicochea
Gregos, Peter
Osborne, Joseph
Ballman, Karla V.
Molina, Ana M.
Sternberg, Cora N.
Nanus, David M.
Bander, Neil Harrison
Tagawa, Scott T.
机构：
[1] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA
[2] Sandra & Edward Meyer Canc Ctr, New York, NY USA
[3] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA
[4] Weill Cornell Med, New York, NY USA
[5] Weill Cornell Med Ctr, New York, NY USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Weill Cornell Med Mol Imaging & Therapeut, Dept Radiol, New York, NY USA
[8] NYP Brooklyn Methodist Hosp, Weill Cornell Med, Brooklyn, NY USA
[9] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[10] Cornell Univ, Weill Med Coll, NewYork Presbyterian Hosp, New York, NY USA
[11] Weill Cornell Med, Hematol Oncol, New York, NY USA
[12] NewYork Presbyterian Hosp, Div Hematol & Med Oncol, Weill Cornell Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS288
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I trial of fractionated-dose 177Lutetium radiolabeled antiprostate-specific membrane antigen (PSMA) monoclonal antibody. J591 (177Lu-J591) for metastatic castration-resistant prostate cancer (CRPC)
    Tagawa, S. T.
    Akhtar, N. H.
    Nikolopoulou, A.
    Vallabhajosula, S.
    Osborne, J.
    Beltran, H.
    Kahn, R.
    Goldsmith, S. J.
    Nanus, D. M.
    Bander, N. H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S702
  • [32] Phase 3 Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (VISION)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 3 - 5
  • [33] Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
    Krause, B.
    de Bono, J.
    Chi, K. N.
    Fizazi, K.
    Herrmann, K.
    Rahbar, K.
    Tagawa, S. T.
    Nordquist, L. T.
    Vaishampayan, N.
    El-Haddad, G.
    Park, C. H.
    Beer, T. M.
    Perez-Contreras, W. J.
    DeSilvio, M.
    Kpamegan, E.
    Gericke, G.
    Messmann, R. A.
    Morris, M. J.
    Sartor, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S63 - S63
  • [34] A phase I dose escalation study of PCUR-101 in men with metastatic castration-resistant prostate cancer (mCRPC).
    Kyriakopoulos, Christos
    Paller, Channing Judith
    Verma, Ajit
    Kader, Karim
    Kittrelle, Jeff
    Borgstrom, Per G.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Phase I trial of fractionated-dose 177Lutetium radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) in patients with metastatic castration-resistant prostate cancer (metCRPC)
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Akhtar, Naveed H.
    Osborne, Joseph
    Beltran, Himisha
    Saran, Ankeeta
    Mileo, Gina
    Ecker, Caryn
    Goldsmith, Stanley J.
    Nanus, David M.
    Bander, Neil H.
    CANCER RESEARCH, 2012, 72
  • [36] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Fadi Khreish
    Niklas Ebert
    Martin Ries
    Stephan Maus
    Florian Rosar
    Hendrik Bohnenberger
    Tobias Stemler
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 721 - 728
  • [37] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Khreish, Fadi
    Ebert, Niklas
    Ries, Martin
    Maus, Stephan
    Rosar, Florian
    Bohnenberger, Hendrik
    Stemler, Tobias
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (03) : 721 - 728
  • [38] Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer
    Tagawa, Scott T.
    Vallabhajosula, Shenker
    Christos, Paul J.
    Jhanwar, Yuliya S.
    Batra, Jaspreet S.
    Lam, Linda
    Osborne, Joseph
    Beltran, Himisha
    Molina, Ana M.
    Goldsmith, Stanley J.
    Bander, Neil H.
    Nanus, David M.
    CANCER, 2019, 125 (15) : 2561 - 2569
  • [39] Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Kostos, Louise Kathleen
    Lai, William Yu Ching
    Lambroglou, Peter
    Medhurst, Elizabeth
    Buteau, James Patrick
    Sandhu, Shahneen
    Tran, Ben
    Spain, Lavinia Anne
    Conduit, Ciara
    Wallace, Roslyn
    Alipour, Ramin
    Akhurst, Timothy J.
    Kong, Grace
    Cardin, Anthony
    Saghebi, Javad
    Kumar, Aravind Ravi
    Hofman, Michael S.
    Azad, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [40] Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).
    Nauseef, Jones T.
    Thomas, Charlene
    Ho, Benedict
    Zuloaga, Juana Martinez
    Gonzalez, Brian D.
    Sun, Michael
    Sartor, A. Oliver
    Singh, Sharon
    Bissassar, Mahelia
    Fernandez, Escarleth
    Tan, Angela
    Patel, Amie
    Naiz, Muhammad Obaid
    Vallabhajosula, Shankar
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Osborne, Joseph
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345